Search results for: Oncology

Capturing the lived experiences of informal care in acute leukemia

20 November 2025

Share this: Download publication Samantha Nier Claud Theakston Priscila Radu David Mott Nadine Henderson Key takeaways Providing informal care to someone living with acute leukemia imposes a severe multidimensional burden,…

Value, Affordability, and Decision Making

Value, Affordability, and Decision Making Efficient allocation of healthcare budgets requires a clear understanding of whether interventions deliver good value for money. Resource-allocation decisions should therefore follow structured, transparent, and…

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

1 January 2022

A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the tumour rather than by…

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations

1 December 2021

Outcome-based payment (OBP) is a flexible payment mechanism linking the price the NHS pays for a medicine to the outcomes it achieves in practice for NHS patients. In 2019 we…

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

8 January 2020

Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin, face significant methodological and…

What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment

2 January 2020

The NHS Improvement Economics team is part of the Strategy Directorate in NHS Improvement. NHS Improvement aims to implement changes to help improve both quality and efficiency. Recent research by…

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

1 April 2019

The WHO Technical Report: Pricing of cancer medicines and its impacts (“the Report”) was published in order to address requests made in a resolution adopted by the 2018 Seventieth World…

Making Outcome-Based Payment a Reality in the NHS

2 January 2019

This report explores the feasibility of introducing one type of flexible payment mechanism – outcome-based payment (OBP) – for cancer medicines into the NHS in England. OBP could help to…

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

1 December 2016

Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL….